Table 4.
Summary of 177Lu PSMA-617 studies.
| Reference | Study Type | Patients (n) | Treatment (GBq) |
Biologic Activity |
|---|---|---|---|---|
| Rahbar et al. (2017) [92] | Retrospective | 145 | 5.9 | 45% PSA declines |
| Hofman et al. (2018) [93] | Phase 2 | 30 | 7.5 | 57% PSA declines |
| Yadav et al. (2019) [94] | Systematic review and meta-analysis | 671 | 75% PSA declines 75.5% clinical benefit rate overall |
|
| Hofman et al. (2020) [95] | Randomised phase 2 | 200 (LuPSMA (n = 99) or cabazitaxel (n = 101)) |
6–8 | 66% PSA declinesImprovement in PSA-PFS |
Key: PFS: progression-free survival; PSA: prostate-specific antigen.